Background
Methods
Ethics
Study site
Participants
Sample collection
HLA typing
Synthetic peptides and peptide pools
15mer pool | C-HLA A01 | C-HLA A02 | C-HLA A03 | C-HLA A24 | C-HLA B27 |
---|---|---|---|---|---|
Cp1 |
FVEALFQEY
a
(B07)
a
LFVEALFQEY
a (B07)e (A01, B44)f (A03,)f EALFQEYQCe (B27)f
|
SVSSFLFVEA
a (A02
a, A30)f
FLFVEALFQE
a, f
(A01A24)
a
ILSVSSFLFV
b (A24)e (A02)f
MMRKLAILSV
c, e(A01A03)e
| QCYGSSSNTRe (B27)f CYGSSSNTRe (B27)f
|
SFLFVEALF
a (A01A24, A24)e, f
AILSVSSFLF
a (B07)e (B58)f
| LAILSVSSFe (B07, B27, B62)e (B27)f ALFQEYQCYe (A01, B27, B62)e YQCYGSSSNe (B62)e (B27)f SSFLFVEALe (B62)e (A01)e
|
Cp2 | |||||
Cp3 | |||||
Cp4 | |||||
Cp5 | |||||
Cp6 |
EPSDKHIKEY
b (B07, B44)f
|
YLNKIQNSL
a, d (A01, B08)e
|
EYLNKIQNSL
b (A02, A24, B08, B27)e (A02, B27)f
| IQNSLSTEWe (B27, B62)e (B07, B27)f
| |
Cp7 | SVTCGNGIQVe, f
|
VTCGNGIQVR
b
| IQNSLSTEWe (B27, B62)e (B07, B27)f
| ||
Cp8 | ELDYANDIEKg (A01)e
| ||||
Cp9 |
SVFNVVNSSI
a, f
(A24)
a (B27)f NVVNSSIGLIa, f
GLIMVLSFL
b, f
| ELDYANDIEKg (A01)e
| KMEKCSSVFe (A01, B27, B62)e (B44)f
IMVLSFLFL
e
(A02)
a (A24, B27)f
LIMVLSFLF
a (A01A24)a (A01, A24, B27, B62)e (A24, B27)f
|
15mer pool | HLA A01 | HLA A02 | HLA A03 | HLA A24 | HLA B07 | HLA B44 |
---|---|---|---|---|---|---|
Ap1 | LLSAFEFTYb (B07)b (A03, B58)c GQNYWEHPYb (B27)c
| KLYCVLLLSAb (A03)b (A02, A03, A30)c SAFEFTYMIb (A01)b
| EFTYMINFGRb (A03)c DVYRPINEHRb, c (A03)c
| LYCVLLLSAFb (B07)b
| YPLHQEHTYb, c
|
FEFTYMINF
a, c (B27)c
YEYPLHQEH
a, c (B27)c
|
Ap2 | NYMGNPWTEYb (B07, B44)b (A01A24, B27)c
| NLFSSIEIVb, c YMGNPWTEYMb, c (A01, B44)b (B27)c
| LFSSIEIVERb, c
| DENTLQHAYb, c (A01, B07)b
QEQNLFSSIb (B27)c IEIVERSNYb, c
| ||
Ap3 | YMAKYDIEEVb, c (B27)c
| TQYRLPSGKb, c (A34, A01A03)c
| ||||
Ap4 |
TLDEMRHFY
a (B07)b (A03, A01)c
MRHFYKDNKY
a (B27)c
LTPVATGNQYb
| MSPMTLDEMRb (B07)b
TLDEMRHFYKb (A01)b (A01)c
| QYLKDGGFAFb (A01, A02, B07, B44)c
| TEPLMSPMTLb (B07)b
| ||
Ap6 | DISFQNYTYb (B07)b (B27, B58)c
| NSMFCFRPAKb, c (A02)b, c (A03, A01A03, A30, B27)c SFQNYTYLSKb
| CPRKNLQNAb, c
| |||
Ap7 | LSASDQPKQYb (A01, B27, B58)c
| IPHVNEFPAb, c
|
NEFPAIDLF
a, c FECNKLVFELb, c (A02, B44, B27)c
| |||
Ap8 | HGKGYNWGNYb (A30, B27)c
|
TQKCEIFNV
a (B27)c FLPTGAFKAb, c ETQKCEIFNVa, c CLINNSSYIa (B27)c
| RYKSHGKGYb (A01)b (A01A03, A30, B27)c SAFLPTGAFKb, c (B07)b (B27)c
| TETQKCEIFb
| ||
Ap9 | VENNFPCSLYb (B44)b (B27, B44)c
| CLINNSSYIb, c (B27)c
| SLYKDEIMKb, c (B27)c (B27, A01A03)c
| FPCSLYKDEIb
HPIEVENNFb, c
| VENNFPCSLb
VENNFPCSLYb, c (A01)b (B27, B44)c
| |
Ap10 | EVTSNNEVVVb, c IIIASSAAVb, c
| FISDDKDSLKb, c (A02)b,c RFFVCKCVERb, c
| KPTYDKMKIIb, c
|
NEVVVKEEY
a, c
| ||
Ap11 | AVLATILMVb, c VLATILMVYLb, c (A01, A03)b (A30)c
| VLATILMVYb (A01)c TILMVYLYKRb ILMVYLYKRKb (A02)b (A03)c
| ||||
Ap12 | TTPVLMEKPYb (B07) | EASFWGEEKRb (A34)c HTTPVLMEKb, c
| RASHTTPVLb (A02, B07, B27, B58)c
|
Ex vivo ELISpot IFN-γ assays
Data analysis
Results
Ex vivo ELISpot IFN-γ responses to CSP overlapping peptide pools
Subject | HLA supertype | CSP 15mer pool | CSP HLA pool | Interpretation |
---|---|---|---|---|
HLA-typed | ||||
v01 |
A01 A03 B27 B27
| Cp9 | C-HLA A03
|
A03 Matcheda
A03 pool contains promiscuous A01 and B27 epitopesb
|
v02 |
A02 A03 B27 B44
| NEG | C-HLA A01, C-HLA A02, C-HLA A03
|
A02, A03 Matcheda A01 pool contains promiscuous A03, B27 and B44 epitopesb
A02 pool contains promiscuous B27 epitopeb
A03 pool contains promiscuous B27 epitopesb
|
v04 |
A01 A24 B27 B27
| Cp1 | NEG | Cp1 pool contains matched identified A01, A24 and B27 epitopesc
Cp1 pool contains matched promiscuous A01, A24 and B27 epitopesd
|
v05 |
A03 A01A03 B27 B44
| Cp1, Cp9 | NEG | Cp1 pool contains matched identified A03 and B27 epitopesc and promiscuous A03 and B44 epitopesd
Cp9 pool contains matched identified B27 and promiscuous B44 epitopesd
|
v10 |
A02 A02 B07 B07 | Cp9 | NEG | Cp9 pool contains matched A02 epitopesc
|
v12 | A01A24 A03 B07 B27
| Cp6 | NEG | Cp6 pool contains promiscuous B07 and B27 epitopesd
|
v16 |
A03 A03 B27 B58
| Cp9 | C-HLA A01 | A01 pool contains promiscuous A03 and B27 epitopesb
Cp9 pool contains promiscuous A01, B27 and B58 epitopesd
|
HLA not typed | ||||
v13 | NEG | C-HLA A24 | Probably A24 matchedb
A24 pool contains promiscuous A02, B07, B27 and B58 epitopesb
| |
v14 | Cp9 | C-HLA A01, C-HLA A02, C-HLA A24
| Probably A02 matched as Cp9 contains identified A02 epitopesa,c
Cp9 pool contains promiscuous A01 and A24 epitopesd
| |
v30 | NEG | C-HLA B27 | Probably B27 matcheda
B27 pool contains identified promiscuous A01A24 and A02 epitopes, and predicted A01, A24, , B07, B58 and B62 epitopesb
| |
v23 | Cp4 | NEG | No HLA prediction possiblee
| |
v31 | Cp9 | NEG | No HLA prediction possiblee
| |
No. positive | 9 (26%) | 6 (17%) | ||
Total Positive | 12 (34%) |
Ex vivo ELISpot IFN-γ responses to predicted HLA-binding CSP peptide pools
Interpretation of responses to CSP 15mer peptide pools and HLA pools
Ex vivo ELISpot IFN-γ responses to the AMA1 peptide pools
Subject | HLA supertype | AMA1 15mer pool | AMA1 HLA pool | Interpretation |
---|---|---|---|---|
HLA-typed | ||||
v01 |
A01 A03 B27 B27
| Ap1, Ap6 |
A01, B44 |
A01 Matcheda
B44 pool contains promiscuous A01 and B27 epitopesb
A01 pool contains promiscuous A03 and B27 epitopesb
Ap1 and Ap6 pools contain promiscuous A01, A03 and B27 epitopesd
|
v02 |
A02 A03 B27 B44
| NEG |
A02
|
A02 Matcheda
A02 contains promiscuous A01, A03 and B44 epitopesd
|
v03 |
A01 A03 B07 B58 | NEG | A02 | A02 pool contains promiscuous A01 and A03 epitopesb
|
v04 |
A01 A24 B27 B27
| Ap2, Ap6 | NEG | Ap2 pool contains matching A01 epitopesc
Ap6 pool contains matching A01 epitopesc, and promiscuous B27 epitopesd
|
v05 |
A03
A01A03 B27 B44 | Ap6 |
A03
|
A03 Matcheda
A03 contains promiscuous A01A03, A03 and B27 epitopesd
|
v08 | A01A03 A02 B27 B44
| Ap1 | NEG | Ap1 pool contains matching A02 and B44 epitopesc, and promiscuous B27 epitopesd
|
v10 |
A02 A02 B07 B07
| NEG |
A02, A03 |
A02 matcheda
A03 pool contains promiscuous A02 and B07 epitopesd
|
v12 | A01A24 A03 B07 B27
| NEG | A02 | A02 pool contains promiscuous A03 and B27 epitopesd
|
v16 |
A03 A03 B27 B58
| Ap2, Ap6, Ap11 | A02 | A02 contains promiscuous A03 and B27 epitopesd
Ap6 contains promiscuous A03, B27 and B58 epitopesd
|
v17 |
A01A03 A03 B07 B44
| Ap6 | NEG | Ap6 contains matching A03 and B07 epitopesc, and promiscuous A01A03 and B07 epitopesd
|
v19 |
A03 A24 B44 B62 | NEG |
A03
|
A03 Matcheda
|
HLA not typed | ||||
v06 | Ap1 |
A02, A03
| Ap1 pool contains matching A02 and A03 epitopese
| |
v09 | Ap1, Ap6 |
B07
| Ap1 and Ap6 pools contain matching B07 epitopese
| |
v13 | Ap7 | A24 | Ap7 and A24 contains promiscuous A01, A02
and
B44 epitopese,f
| |
v14 | Ap1, Ap2, Ap6 |
A01, A02, A03, A24, B07
| Ap1 pool contains matching A01, A02, A03, A24, B07 and B44 epitopese
Ap2 contains matching A01, A02 and A03 epitopese, and promiscuous B07 epitopesf
Ap6 contains matching A01, A03 and B07 epitopes5, and promiscuous B07 epitopesf
| |
v22 | Ap6 |
A03
| Ap6 pool contains matching A03 epitopese
| |
v30 | Ap1, Ap2, Ap3, Ap6 |
A03, B07
| Ap1, Ap2, Ap3 and Ap6 pools contain matching A03 epitopese
Ap1 and Ap6 pools contain matching B07 epitopese
| |
v31 | Ap6 |
A03
| Ap6 pool contains matching A03 epitopese
| |
v32 | Ap1 |
A03
| Ap1 pool contains matching A03 epitopese
| |
v33 | Ap1, Ap6 |
A03
| Ap1 and Ap6 pools contain matching A03 epitopese
| |
v18 | Ap3, Ap4, Ap7, Ap8, Ap10 | NEG | No prediction possibleg
| |
v07 | Ap1, Ap6, Ap11 | NEG | No prediction possibleg
| |
v20 | NEG | A03 | Probably contains A03-matched epitopese
| |
v21 | Ap2 | NEG | No prediction possibleg
| |
v23 | Ap6 | NEG | No prediction possibleg
| |
v26 | Ap6 | NEG | No prediction possibleg
| |
v28 | Ap6 | NEG | No prediction possibleg
| |
v34 | Ap6 | NEG | No prediction possibleg
| |
No. positive | 22 (63%) | 18 (51%) | ||
Total Positive | 28 (80%) |